Novo Nordisk got European approval to move forward with its planned buyout of U.S.-based drug manufacturer Catalent, which produces much of its popular obesity drug Wegovy. That leaves the U.S.
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.
They are currently approved for treating diabetes, obesity and those with a history of cardiovascular disease in people who ...
Joe Breen, 38, is one of thousands of people whose experiences with GLP-1s such as Ozempic and Wegovy have radically changed their relationship with alcohol. Are these drugs the future for treating ...
Azelaprag, the company’s main clinical candidate, is an oral apelin receptor agonist designed to amplify the weight loss ...
According to a sneak peek of the data from one of Eli Lilly's (NYSE: LLY) late-stage clinical trials, the cardiometabolic ...
Lilly's rival Danish firm Novo Nordisk is also working to bring its obesity drug Wegovy (Semaglutide) to India soon, and ...